Anergix LLC has developed a proprietary cell therapy technology for the deliver of peptides in vivo. Our lead program focuses on the treatment of multiple sclerosis (MS) in which patients will be receive peptides, whose sequences are derived from the proteins of myelin, delivered in vivo. Anergix was awarded an NIH SBIR grant for studies to satisfy FDA requirements prior to the initiation of a Phase I clinical trial.